0803 GMT - Novartis's guidance for this year is a bit soft on core earnings before interest and taxes, Morgan Stanley analysts Thibault Boutherin and Sarita Kapila write in a research note. The Swiss drugmaker also reported some minor delays in trial results that could cause shares to underperform, they say. The company's forecast of a decline in core EBIT "reflects the impact of [loss of patent exclusivity] and expected margin dilution from the Avidity acquisition," the analysts add. (william.gray@wsj.com)
(END) Dow Jones Newswires
February 04, 2026 03:04 ET (08:04 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.